HOME >> BIOLOGY >> NEWS
Report in PNAS on role of nephrin, the kidney filter protein



An artist's rendering of a glomerular capillary surrounded by podocyte pedicels which are interconnected by the slit diaphragm at the capillary-podocyte pedicel interface.

Full size image available through contact
Studies identify nephrin as a key target for therapeutic strategies to improve kidney function

Research Triangle Park, N.C. -- July 6, 1999 -- BioStratum Incorporated announced today the publication in the journal Proceedings of the National Academy of Sciences (volume 96, pages 7962-7967) of the paper entitled "Nephrin is specifically located at the slit diaphragm of the glomerular podocyte". The work was completed in the laboratory of one of BioStratum's founding scientists, Dr. Karl Tryggvason of the Karolinska Institute, Stockholm, Sweden.

In this paper, nephrin is found at the 'slit diaphragm', also referred to as the 'slit membrane', an important structure in the kidney's filtration barrier. Nephrin appears to form a 'zipper-like' filtration structure that functions both as a key structural motif which organizes and maintains the integrity of the filtration barrier as well as a porous filtration structure that allows the liquid portion of the blood to pass but not plasma proteins.

A break-down in the kidney's ability to filter proteins is a common occurrence in most kidney diseases, and results in proteinurea (protein in the urine). Proteinuria is not only a consequence of kidney disease, but also is generally regarded as a major contributing factor to the development of end-stage renal disease, a condition requiring renal placement therapy (transplantation, dialysis). Nephrin's key role in the kidney's filtration barrier suggests that treatments which increase the production of this protein or restore its function are likely to improve kidney function by restoring the kidney's ability to filter proteins. BioStratum owns
'"/>

Contact: Matthew Knight
m.knight@noonanrusso.com
212-696 4455
Noonan/Russo Communications
5-Jul-1999


Page: 1 2 3

Related biology news :

1. Report outlines vision and recommendations for microbiology in the 21st Century
2. Report outlines steps needed to lessen smallpox threat
3. Reporters from Science Magazine to receive ASM Public Communications Award
4. Report in BioScience details global decline of nonmarine mollusks
5. National Academies news: Report on EPAs particulate matter research
6. Report details growing climate change threat to coral reefs
7. Report to aid nation in managing freshwaters
8. Report examines use of antibiotics in agriculture
9. Report offers action plan for curbing diseases that kill millions
10. Report focuses on the science and safety of genetically modified crops
11. Report considers role of science in a world made vulnerable by terrorism

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Report PNAS role nephrin the kidney filter protein

(Date:5/21/2013)... , May 21, 2013 Royal Philips Electronics ... the world,s first portable ultrasound with Philips, industry leading ... capability. The CX50 xMATRIX with available Live 3D TEE ... at the EuroPCR, official meeting for the ... Since its launch in 2012, Philips CX50 ...
(Date:5/21/2013)... modifications, which alter the way genes function without ... detected in the blood of pregnant women during ... foretell depression in the weeks after giving birth, ... debilitating. , The findings of the small study ... the journal Molecular Psychiatry . , "Postpartum ...
(Date:5/20/2013)... to the antibiotic colistin are also commonly resistant ... according to a study in mBio , ... for Microbiology. Cross-resistance to colistin and host antimicrobials ... against bacterial attack, could mean that patients with ... a crippled immune response. Colistin is a last-line ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
(Date:5/21/2013)... Toronto, Canada (PRWEB) May 21, 2013 ... there is a strong push within the industry ... Development and Manufacturing Organizations and pharma companies often ... time frames. , Microtablets, developed in collaboration with ... how effective outsourcing can bring products to market ...
(Date:5/21/2013)... May 21, 2013 Many have long ... contributor to acne. Recently physicians from Clinical Psychiatry.com ... stress on the skin, and suggested using hypnotherapy ... the chemicals produced from stress that cause acne. , ... negative feelings acne brings about, stress causes changes in ...
(Date:5/21/2013)... Emerson Resources Inc. , a premier pharmaceutical ... Company’s Chief Executive Officer and Chairman of the Board, ... service. As part of Emerson Resources’ planned leadership succession ... as Dr. Signorino’s successor. , Dr. Signorino is ... a significant contribution to the field during his extensive ...
(Date:5/21/2013)... 21, 2013  MacroGenics, Inc. today announced that ... (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in ... oncoprotein," will be presented at the 2013 Annual ... during the Developmental Therapeutics - Immunotherapy Oral Abstract ... 4:30 PM.  The presentation will describe the results ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: